Investor Presentation June 2017 Forward-looking Statements and - - PowerPoint PPT Presentation
Investor Presentation June 2017 Forward-looking Statements and - - PowerPoint PPT Presentation
Investor Presentation June 2017 Forward-looking Statements and Non-GAAP Information This presentation may include projections and other forward -looking statements within the meaning of the Private Securities Litigation Reform Act of
Investor Presentation, June 2017
Forward-looking Statements and Non-GAAP Information
2
- This presentation may include projections and other “forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements relate to future events and expectations and involve unknown risks and
- uncertainties. Omega’s actual results or actions may differ materially from those projected in the forward-looking statements.
For a summary of the specific risk factors that could cause results to differ materially from those expressed in the forward-looking statements, see Omega’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission.
- This presentation may contain certain non-GAAP financial information including EBITDA, Adjusted EBITDA, Total Adjusted Debt
(aka, Funded Debt), Adjusted FFO, FAD, Total Cash Fixed Charges and certain related ratios. A reconciliation of these non-GAAP disclosures is available in the Exhibit to this presentation or on our website under “Non-GAAP Financial Measures” at www.omegahealthcare.com. Other financial information is also available on our website.
- Information is provided as of March 31, 2017, unless specifically stated otherwise. We assume no duty to update or supplement
the information provided.
Omega Overview
Investor Presentation, June 2017
Omega Overview: Key Credit Highlights
4
Financial Strength Portfolio Strength
Strong portfolio TTM rent coverage of 1.69x (EBITDARM) and 1.33x (EBITDAR) at 12/31/2016 Geographic and operator diversification with 77 operators across 42 states and the United
Kingdom
No upcoming material lease expirations and no material lease renewal risk Favorable near term supply and demand outlook Conservative leverage level with Funded Debt / Adj. EBITDA of 4.8x (Q1 2017), in-line with
- ur leverage target
Consistent and stable free cash flow with strong fixed charge coverage of 4.8x (Q1 2017,
see Exhibit I, Non-GAAP Financial Reconciliation, Adjusted EBITDA Reconciliation)
Low Secured debt / Adj. EBITDA of 0.1x and strong commitment to unsecured borrowing
structure with ~$10.1 billion of unencumbered assets
Minimal short-term debt maturities Positive ratings trajectory with history of upgrades and commitment to investment grade
profile
Significant liquidity with $1.1 billion of cash and credit facility availability at 6/1/2017
Experienced Management Team
Senior management team with average tenure of 16+ years Proven ability to execute on strategies Proven ability to handle troubled assets
Investor Presentation, June 2017
Omega Overview: Facility and Investment Overview at March 31, 2017
5
Omega is the largest SNF-focused REIT
As of March 31, 2017, Omega portfolio consisted of 972 (1) operating facilities
Completed over $1.3 billion of investments in 2016 Facility Investment Statistics Revenue Statistics
Skilled Nursing/Transitional Care, 85% Senior Housing, 15% Rental Property 83% Direct Financing Leases 7% Mortgages 7% Other 3%
1) Excludes non-operating facilities either held-for-sale, closed and/or not currently providing patient services
Investor Presentation, June 2017
$0.00 $2.00 $4.00 $6.00 $8.00 $10.00 $12.00 $14.00 $16.00 $18.00 $20.00 $22.00 $24.00 $26.00 $28.00 $30.00 $32.00 $34.00 $36.00 $38.00 $40.00 $42.00 $44.00 $46.00
Financial Overview: Shareholder Returns
6 1/1/2004 to 12/31/2016 OHI Share Price: 235.0% RMZ Index: 96.1% Quarterly Dividends as of 5/15/2017 1 Year Total Growth: 8.6% 3 Year Total Growth: 26.0% 5 Year Total Growth: 50.0% 1/1/2004 to 12/31/2016 Real Estate Investments: 20.5% Operating Revenue: 20.6% Adjusted FFO per Share: 12.1% OHI Share Price: 9.7% Dividend Yield at $0.63/Share Per Quarter 8.0%
(based on closing price on 5/31/2017 of $31.32)
Omega Share Price Growth, 12/2002-5/16/2017 Compounded Annual Growth Rates Total Growth Percentages
Investor Presentation, June 2017
Financial Overview: Shareholder Returns (cont’d)
7 Total Return
- Ann. Equiv.
Ranking (2) 3 Year: 26.2% 8.1% 7th 5 Year: 122.6% 17.3% 2nd 7 Year: 154.8% 14.3% 2nd 10 Year: 246.9% 13.2% 2nd (3)
1) Source: Bloomberg Comparative Analytics 2) Healthcare REIT rankings and average total returns include: VTR, HCP, HCN, LTC, HR, NHI, SNH, SBRA and CCP (1 year only) 3) Ranked 9th among all 173 publicly traded equity REITs. Source: KeyBanc Capital Markets “The Leaderboard”, December 30, 2016
Shareholder Returns Through 12/31/2016 (1) Dividends per Share and Return of Capital % Omega's Total Returns vs Healthcare REIT Average (2)
(Years ending 12/31)
0.0% 50.0% 100.0% 150.0% 200.0% 250.0% 300.0% 3 Year 5 Year 7 Year 10 Year Omega's Total Returns
- Avg. Total Returns of Healthcare REITs
Tax Treatment ($) Tax Treatment (%) Total Dividends Ordinary (1) Income Return of (1) Capital Capital Gain (1) Distribution % Ordinary Income % Return of Capital % Capital Gain Distribution 2012 1.69 0.88 0.81
- 52.3%
47.7% 0.0% 2013 1.86 1.54 0.32
- 82.6%
17.4% 0.0% 2014 2.02 1.83 0.19
- 90.8%
9.2% 0.0% 2015 2.18 1.13 1.05
- 52.0%
48.0% 0.0% 2016 2.36 1.97 0.32 0.07 83.4% 13.6% 3.0% 10.11 $ 7.36 $ 2.68 $ 0.07 $ 72.8% 26.6% 0.7%
1) Rounded to two decimals
Investor Presentation, June 2017
Omega Overview: Recent Announcements
8 2Q 2017
- Increased our quarterly common stock dividend rate to $0.63 per share.
- Redeemed our $400 million 5.875% Senior Notes due 2024
- Issued $550 million 4.75% Senior Notes due 2028 and $150 million 4.50% Senior Notes due 2025
- Closed on a new $1.8 billion unsecured, multi-currency credit facility
- Completed $116 million (£90 million) of new UK investments
1Q 2017
- Increased our quarterly common stock dividend rate to $0.62 per share.
- Completed $7.6 million in new investments
4Q 2016
- Invested approximately $50 million in a joint venture investment.
- Invested $40 million in capital renovation and construction-in-progress projects.
- Increased our quarterly common stock dividend rate to $0.61 per share.
3Q 2016
- Completed $428 million in new investments.
- Invested $38 million in capital renovation and construction-in-progress projects.
- Repurchased an outstanding $180 million secured term loan due 2019.
- Issued $700 million aggregate principal amounts of our 4.375% Senior Notes due 2023.
- Increased our quarterly common stock dividend rate to $0.60 per share.
2Q 2016
- Completed $220 million in new investments.
- Invested $28 million in capital renovation and construction-in-progress projects.
- Increased our quarterly common stock dividend rate to $0.58 per share.
Investor Presentation, June 2017
Omega Overview Proven Track Record of Growth and New Investments
Continue to pursue selective investments
- 2004 New Investments:
$126 million
- 2005 New Investments:
$311 million
- 2006 New Investments:
$203 million
- 2007 New Investments:
$ 46 million
- 2008 New Investments:
$197 million
- 2009 New Investments:
$292 million
- 2010 New Investments:
$638 million
- 2011 New Investments:
$365 million
- 2012 New Investments:
$510 million
- 2013 New Investments:
$621 million
- 2014 New Investments:
$566 million
- 2015 New Investments:
$507 million (1)
- 2016 New Investments:
$1,328 million
- 2017 New Investments:
$124 million
- Additionally, the Company has approximately $287 million committed to its operators for capital
improvement and new construction projects to be completed over the next 24-36 months (as of 6/1/2017)
Continue to pursue accretive transactions
Leverage existing 77 operator relationships
Invest primarily in current core markets
Maintain focus on senior care facilities
Use credit facility to make acquisitions and replenish availability with long-term debt and equity issuances
Approximately $1.1 billion of combined cash and credit facility availability as of June 1, 2017
1)
Investments exclude the approximate $3.9 billion acquisition via merger of Aviv REIT on April 1, 2015
2)
Excludes investments made by Aviv prior to acquisition via merger by Omega
Omega’s Growth Strategy $5.8 billion (2)
9
SNF Industry and Reimbursement Overview
Investor Presentation, June 2017
Attractive Fundamentals: Primary PAC Site
11
SNFs – preferred post-acute care environment with growing demand and limited supply
Medicare Acute Hospital Discharges 43% Sent to Post-Acute SNFs 48% HHAs 39% IRFs 9% LTACHs 3%
Source: MedPAC Data Book, June 2016
Investor Presentation, June 2017
Growth in SNF Census, by Age Cohort
12
<65 210 <65 214 <65 217 <65 220 <65 224 65-74 224 65-74 269 65-74 302 65-74 320 65-74 311 75-84 358 75-84 427 75-84 548 75-84 661 75-84 749 85+ 565 85+ 603 85+ 671 85+ 819 85+ 1,068
- 100
200 300 400 500 600 700 800 900 1,000 1,100 1,200 1,300 1,400 1,500 1,600 1,700 1,800 1,900 2,000 2,100 2,200 2,300 2,400 2,500
2015 2020 2025 2030 2035
Number of SNF Residents (000's)
<65 65-74 75-84 85+
Maximum current SNF capacity
Source: CMS Nursing Home Data Compendium (2015 Edition) for percentage of SNF residents by age cohort and US Census Bureau data for population growth projections by age cohort.
82% 91% 105% 122% 142%
Occupancy
Aging demographics would drive SNF occupancy beyond capacity in less than 10 years without efforts to reduce lengths of stay and increased utilization of alternative care sites.
Investor Presentation, June 2017
Industry Overview: Attractive Fundamentals
13
Supply of facilities and beds to meet increasing future demand is limited due to CON restrictions, increasing occupancy prospects for existing facilities
(figures in 000s, unless
- therwise indicated)
Source: Compiled by American Health Care Association (AHCA) Research Department from CMS OSCAR/CASPER survey data (2009-2016) Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Certified Beds 1,667k 1,670k 1,665k 1,667k 1,666k 1,663k 1,662k 1,662k Patients in Certified Beds 1,400k 1,394k 1,384k 1,383k 1,372k 1,368k 1,357k 1,347k Certified Facilities 15.7k 15.7k 15.6k 15.7k 15.7k 15.6k 15.7k 15.7k 15.0k 15.1k 15.2k 15.3k 15.4k 15.5k 15.6k 15.7k 15.8k 15.9k 16.0k 1,300k 1,350k 1,400k 1,450k 1,500k 1,550k 1,600k 1,650k 1,700k Certified Facilities Beds & Patients
Trend in Certified Nursing Facilities, Beds and Residents
Investor Presentation, June 2017
2009 2010 2011 2012 2013 2014 2015 2016 OHI Occ. % 84.6% 84.1% 84.0% 83.4% 83.3% 84.5% 82.5% 82.2% Industry Occ. % 84.0% 83.4% 83.1% 82.9% 82.3% 82.3% 81.6% 81.1% 65.0% 70.0% 75.0% 80.0% 85.0% 90.0% 95.0%
SNF Industry and Omega Portfolio Occupancy Trends 2009 through 2016
OHI Occ. % Industry Occ. %
Industry Overview: Attractive Fundamentals
14
- Occupancy Rate Trends
Source: Industry data compiled by AHCA Research Department from CMS OSCAR/CASPER survey data (2009-2016)
(1) 2015 and 2016 OHI occupancy reflects inclusion of legacy Aviv REIT facilities
(1)
Investor Presentation, June 2017
50.54 56.78 65.59 75.29 83.63 79.36 83.03 89.31 104.70 120.47 79.43 83.13 86.40 99.99 115.41 79.32 82.79 81.19 91.27 102.83 40 50 60 70 80 90 100 110 120 130 2012 2016 2021 2026 2031 (Millions of Days or Beneficiaries)
Yearly Medicare SNF Volume (Days)
Total Medicare Enrollment (Beneficiaries) Conservative Reduction in LOS Moderate Reduction in LOS Aggressive Reduction in LOS
Industry Overview: Attractive Fundamentals
15
Source: SNF Volume from December 2016 Avalere Health projection model (“Assessment of SNF Reimbursement and Utilization Landscape” Report); Medicare enrollment from 2016 Medicare Trustees’ Report
SNF Medicare patient days projected to grow due to increasing enrollment, even while lengths
- f stay decline under alternative payment models (bundling, managed care, ACOs, VBP)
Note: Conservative, Moderate, and Aggressive refer to model assumptions about rate of growth in alternative payment models, which reduce Lengths of Stay (LOS)
Investor Presentation, June 2017
$115 $125 $135 $145 $155 $165 $175 $185 $195 $205 $215
Medicaid PPD
$300 $325 $350 $375 $400 $425 $450 $475 $500
$PPD
Medicare PPD
Industry Overview: Reimbursement Outlook
16
Medicare
- Growth in alternative payment models expected to continue under new DHHS/CMS leadership, but at a slower pace
- Inflationary increases for fee-for-service PPS rates reduced to 1% for the next two years under current RUG classification system
- Potential CMS PPS reform commencing in 2018 would eliminate RUG system and use alternative patient characteristics system,
effectively reducing payments for therapy services while enhancing payments for complex nursing care and incentivizing lower lengths of stay
Medicaid
- Congressional legislation under consideration to repeal/replace ACA expected to include Medicaid reform, which will likely change
federal funding to states from current matching program to capped per capita program; impact currently unknown but long phase-in process likely to minimize state financial burden while eligibility and other potential state reforms enacted
- Omega's geographic diversification helps minimize impact of rate changes in any particular state
Average Medicare and Medicaid Rates by Quarter for Omega’s Entire Portfolio (1) (through December 31, 2016)
1) Rate for each month is calculated by dividing total Portfolio Operator Medicare/Medicaid revenues by total Portfolio Operator Medicare/Medicaid days.
Portfolio Overview
Investor Presentation, June 2017
Portfolio Overview: Summary
18
- As of March 31, 2017
- 972 operating healthcare facilities, located in 42 states and the UK, operated by 77 third-
party operators
- Gross real estate investments of approximately $9.2B
- Focused on leasing long-term care facilities (primarily skilled nursing facilities) to strong
regional and local operators
- Long term triple-net master leases with cross collateralization provisions
- Strong credit profiles
- Security deposits of three to six months
- Monthly reporting requirements
- Property level expenses are operator’s responsibility (labor, insurance, property taxes, capital
expenditures)
- Omega receives fixed rent payments from tenants, with annual escalators
- Operators receive revenues through reimbursement of Medicare, Medicaid and private pay for
services
Investor Presentation, June 2017
Facility Map at March 31, 2017
19
1) Many operators have facilities in multiple states 2) Excludes non-operating facilities, closed and/or not currently providing patient services 3) Includes New York City 2nd Avenue development project
(No. of Operators No. of Facilities)
<10 facilities 10 to 20 facilities >20 facilities State Concentration Key
319 MS 310 NM 68 WI 36 NV 855 CA 519 WA 511 ID 2 9 AZ 13108 TX 314 CO 311 IA 519 MO 432 AR 213 LA 417 IL 759 IN 1285 OH 331 KY 841 TN 29 AL 1295 FL 513 GA 531 NC
411 WV
742 PA 310 MA 13 NH 11 VT 14 RI 212 MD 316 KS 49 OK MI 346 WY ND SD 11 NY NJ ME 24 UT 47 OR 322 SC 517 VA 12 MT 17 NE 13 MN 16 CT
135
United Kingdom
Operators: 77 (1) Facilities: 972 (2) States: 42 (3) Foreign Countries: 1 (UK)
Investor Presentation, June 2017
Ohio 10% Florida 10% Texas 8% Michigan 7% California 5% Indiana 5% Pennsylvania 5% Tennessee 5% North Carolina3% South Carolina 3% Other States 39%
Portfolio Overview: Omega State Diversification as of March 31, 2017
20
Rent/Interest by State 1
1) Rent excludes all GAAP required non-cash straight-line or lease inducement revenue 2) Excludes facilities closed and/or not currently providing patient services 3) Many operators have facilities in multiple states
($ in thousands)
State 1Q17 Annualized Contractual Rent/Interest % of Total Rent/Interest Facilities (2) Operators (3)
- 1. Ohio
87,854 10.4% 85 12
- 2. Florida
85,742 10.1% 95 12
- 3. Texas
71,375 8.4% 108 13
- 4. Michigan
55,207 6.5% 46 3
- 5. California
44,203 5.2% 55 8
- 6. Pennsylvania
43,742 5.2% 42 7
- 7. Indiana
43,461 5.1% 59 7
- 8. Tennessee
38,802 4.6% 41 8
- 9. North Carolina
25,788 3.0% 31 5
- 10. South Carolina
24,225 2.9% 22 3
Other States
325,998 38.5%
388 93 TOTAL 846,397 $ 100.0% 972
77
Investor Presentation, June 2017
Ciena, $82.3MM Signature , $61.8MM Genesis , $57.3MM Ark, $54.MM Communicare , $46.1MM Saber, $41.1MM HHC , $34.5MM Maplewood , $33.1MM Guardian , … Diversicare , $28.1MM Remaining 67 Operators, $378.8MM
Portfolio Overview: Omega Operator Diversification as of March 31, 2017
21
Rent/Interest by Operator *
1) Excludes facilities closed and/or not currently providing patient services 2) Rent excludes all GAAP required non-cash straight-line or lease inducement revenue
($ in thousands)
- No. of
Properties (1) Revenue (2) % Revenue 1 Ciena 68 82,268 $ 10% 2 Signature 62 61,801 7% 3 Genesis 50 57,293 7% 4 Ark 58 54,001 6% 5 Communicare 32 46,107 5% 6 Saber 46 41,098 5% 7 HHC 44 34,544 4% 8 Maplewood 13 33,102 4% 9 Guardian 31 29,303 4% 10 Diversicare 35 28,123 3% Remaining 67 Operators 533 378,756 45% 972 846,397 $ 100%
Investor Presentation, June 2017
Portfolio Overview: Capital Investment Summary as of June 1, 2017
22
Commitment Year Location # of Projects Property Type Initial Cash Yield Beds/ Units Investment Commitment Inception Date Funding Land Cost Total Capitalized Interest/Other Remaining Commitment Estimated In Service Date New Builds 2014 Brewster, MA 1 ALF 9.00% 131 37,288,000 36,650,910 6,288,000
- 637,090
Dec-16 2014 Vara, MA 1 ALF 9.00% 75 23,835,652 16,385,933 3,864,292
- 7,449,719
Nov-17 2014 West Yarmouth, MA 1 ALF 9.00% 126 10,230,500 537,086
- 9,693,414
TBD 2014 Middleburg, FL 1 SNF 9.00% 120 17,750,000 3,942,791 1,529,599
- 13,807,209
Dec-18 2015 Webster, TX 1 SNF 9.00% 120 16,714,450 4,760,643 2,211,330
- 11,953,807
Oct-17 2015 Pensacola, FL 1 SNF 8.75% 90 20,788,990 13,698,205 2,450,395 45,549 7,090,785 Jul-17 2015 Tampa Lakes, FL 1 SNF 9.25% 179 26,500,000 24,281,076 1,337,184 375,234 2,218,924 Mar-17 2015 Polk County,FL 1 SNF 9.00% 120 18,000,000 5,609,399 823,859
- 12,390,601
Dec-17 2015 2nd Ave, NY 1 ALF/MC 7.00% 214 249,628,480 133,006,940 122,579,202
- 116,621,540
Apr-19 2015 Five Forks, GA 1 ALF 8.75% 48 10,600,000 9,626,309 1,134,935 51,917 973,691 Jan-17 2015 Baton Rouge, LA 1 ALF 8.75% 50 11,700,000 10,708,779 2,382,941 198,537 991,221 Sep-17 2015 Watkins, VA 1 ALF 8.75% 48 11,700,000 6,691,448 1,802,533 71,261 5,008,552 Jan-17 2016 Viera, FL 1 SNF 8.75% 131 26,500,000 3,936,036 2,558,000
- 22,563,964
Jul-18 2016 Pensacola, FL 1 SNF 6.00% 90 19,400,000 944,956 930,173
- 18,455,044
Aug-18 2016 Brunswick, NC 1 SNF 9.00% 100 11,650,000 5,500,496
- 6,149,504
Sep-17 15 1,642 512,286,072 $ 276,281,006 $ 149,892,443 $ 742,500 $ 236,005,067 $ Additional Capex (excluding New Builds) 104 157,752,733 $ 106,878,630 $ 50,874,102 $ Total: 119 670,038,805 $ 383,159,636 $ 149,892,443 $ 742,500 $ 286,879,169 $
Investor Presentation, June 2017
Portfolio Overview: Omega’s Strong Portfolio Rent Coverage
23
(1) 1) Prior to 2015, Rent Coverages were reported at one decimal.
Period Trailing Twelve Months (TTM) Period Trailing Twelve Months (TTM) Ending EBITDARM EBITDAR Ending EBITDARM EBITDAR 03/31/02 1.5 1.1 03/31/10 2.0 1.6 06/30/02 1.6 1.1 06/30/10 2.0 1.6 09/30/02 1.6 1.1 09/30/10 2.1 1.6 12/31/02 1.5 1.1 12/31/10 2.1 1.7 03/31/03 1.5 1.1 03/31/11 2.2 1.8 06/30/03 1.5 1.1 06/30/11 2.3 1.8 09/30/03 1.5 1.1 09/30/11 2.3 1.8 12/31/03 1.5 1.1 12/31/11 2.2 1.8 3/31/04 1.6 1.1 3/31/12 2.1 1.7 6/30/04 1.7 1.2 6/30/12 2.0 1.6 9/30/04 1.8 1.3 9/30/12 2.0 1.5 12/31/04 1.9 1.4 12/31/12 2.0 1.5 3/31/05 1.8 1.4 3/31/13 2.0 1.5 6/30/05 1.9 1.4 6/30/13 1.9 1.5 9/30/05 1.9 1.5 9/30/13 1.9 1.5 12/31/05 2.0 1.5 12/31/13 1.9 1.4 3/31/06 2.0 1.6 3/31/14 1.8 1.4 6/30/06 2.1 1.6 6/30/14 1.8 1.4 9/30/06 2.1 1.6 9/30/14 1.8 1.4 12/31/06 2.1 1.7 12/31/14 1.8 1.4 3/31/07 2.1 1.7 3/31/15 1.78 1.38 6/30/07 2.2 1.7 6/30/15 1.80 1.41 9/30/07 2.2 1.8 9/30/15 1.79 1.40 12/31/07 2.2 1.8 12/31/15 1.78 1.40 3/31/08 2.2 1.8 3/31/16 1.75 1.37 6/30/08 2.1 1.7 6/30/16 1.72 1.34 9/30/08 2.1 1.7 9/30/16 1.68 1.31 12/31/08 2.0 1.6 12/31/16 1.69 1.33 3/31/09 2.0 1.6 6/30/09 2.0 1.6 9/30/09 2.0 1.6 12/31/09 2.0 1.6 1.0
1.3 1.5 1.8 2.0 2.3 2.5
TTM EBITDARM & EBITDAR Coverage 3/31/2002 to 12/31/2016, Quarterly
EBITDARM EBITDAR
Investor Presentation, June 2017
Portfolio Overview: Omega Lease and Mortgage Revenue Expirations as of March 31, 2017
24
Minimal Near Term Expirations
- Approximately 90% of portfolio expirations occur after 2021
- Combined EBITDAR coverage of leases expiring through 2021 is 1.36x (1)
Note: Expiration percentages based on 1Q 2017 contractual rents and interest, annualized. 1) Operator coverage data as of December 31, 2016
0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% 70.0% 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 Thereafter
0.9% 4.7% 0.4% 1.7% 1.4% 8.1% 6.1% 7.6% 2.6% 2.9% 63.5%
Financial Overview
Investor Presentation, June 2017
Financial Overview: Consistent Financial Policy
26
Q1 2017 (unless otherwise noted)
- Conservative capitalization
- Debt to adjusted EBITDA ratio of 4.0x – 5.0x:
4.8x (see Exhibit 1)
- Significant liquidity
- $1.25B revolving credit facility:
$1.0 billion of availability (as of June 1, 2017)
- Well-laddered debt maturities:
No material maturities until 2022 (assuming allowable credit facility extensions)
- Financial flexibility
- Capital markets access
- Minimize encumbered assets
- Funded Debt to Total Asset Value:
46%
- Adjusted Fixed Charge Ratio >3.5x:
4.8x (see Exhibit 1)
- Stable dividend payout ratio
- Less than 85% of AFFO:
Payout of 73.5%
- Less than 90% of AFAD:
Payout of 81.5%
- 19 consecutive quarterly dividend increases:
$0.63 as of Q2 2017
Investor Presentation, June 2017
Financial Overview: Growth Strategy
27
- Pursue selective acquisitions
- Leverage existing 77 operator relationships
- Invest primarily in current core markets
- Maintain focus on senior care facilities
- Use credit facility to make acquisitions and replenish availability with long
term debt and equity issuances
Investor Presentation, June 2017
2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 1Q 2017 Acquisitions 114,287 245,550 196,000 39,500 112,135 269,393 588,718 187,696 468,153 561,190 131,689 406,953 972,190 124,000 Mortgages 6,500 61,750
- 345
70,000 3,509 20,656 130,041 11,969 3,379 412,307 47,696 31,482
- Capex
5,536 3,821 6,805 6,187 14,683 18,609 28,403 18,896 29,436 56,289 21,514 52,295 41,033 13,865 CIP (2)
- 62,197
13,673 Other (1)
- 28,000
- 221,367
2,229
- 200,000
400,000 600,000 800,000 1,000,000 1,200,000 1,400,000
Other (1) CIP (2) Capex Mortgages Acquisitions
Financial Overview: Investment History
28
(in thousands)
Investments, 2004 through March 31, 2017
$4.7 billion of new investments since January, 2010 (3)
(3) 1) Consists primarily of Mezzanine and JV investments 2) Included in “Acquisitions” prior to 2016 3) Excludes $3.9B Aviv acquisition via merger by Omega on April 1, 2015 4) Includes UK investment closed in May
Total 126,323 311,121 202,805 46,032 196,818 291,511 637,777 364,633 509,558 620,858 565,510 506,944 1,328,269 153,767
(4)
Investor Presentation, June 2017
$87 $110 $136 $160 $170 $179 $251 $292 $350 $419 $505 $744 $901
$0 $100 $200 $300 $400 $500 $600 $700 $800 $900 $1,000 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
$0.94 $1.13 $1.29 $1.32 $1.50 $1.80 $2.50 $2.83 $3.33 $3.92 $4.47 $8.11 $9.17
$0.00 $1.00 $2.00 $3.00 $4.00 $5.00 $6.00 $7.00 $8.00 $9.00 $10.00 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Financial Overview: Attractive Growth Profile
29
Core Operations Revenue Gross Investments
($ in billions) ($ in millions)
Investor Presentation, June 2017
$52 $77 $91 $109 $123 $156 $193 $236 $299 $363 $564 $689 $0 $100 $200 $300 $400 $500 $600 $700 $800 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 $101 $127 $145 $159 $170 $236 $279 $334 $402 $487 $716 $870 $0 $100 $200 $300 $400 $500 $600 $700 $800 $900 $1,000 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Financial Overview: Attractive Growth Profile
30
Adjusted Funds from Operations (2) Adjusted EBITDA(1)
1) Reflects adjustments for nursing home revenues and expenses, nonrecurring items, restricted stock amortization, provisions for impairment, provisions for uncollectible accounts, and adjustments to fair value (see Exhibit) 2) See the Non-GAAP reconciliations provided on our website at www.omegahealtcare.com under “Investor Relations” “Financial Information” “Non-GAAP Financial Measures”
($ in millions) ($ in millions)
$225.3M for Q1:17 $176.7M for Q1:17
Investor Presentation, June 2017
3.8x 3.1x 3.3x 3.5x 4.0x 4.1x 4.7x 5.1x 0.0x 1.0x 2.0x 3.0x 4.0x 5.0x 6.0x 2009 2010 2011 2012 2013 2014 2015 2016 3.7x 4.3x 4.8x 4.7x 4.4x 4.6x 4.5x 4.7x 1.3x 0.7x 0.9x 0.9x 0.6x 0.5x 0.3x 0.1x 0.0x 1.0x 2.0x 3.0x 4.0x 5.0x 6.0x 2009 2010 2011 2012 2013 2014 2015 2016
Total Debt / Adj. EBITDA Secured Debt / Adj. EBITDA
Financial Overview: Conservative Capitalization
31
(1) Adjusted annualized EBITDA includes revenue for all new investments as if they occurred January 1 of their respective year. Debt amounts exclude the fair value adjustments on HUD debt and the net premium or discount on the unsecured notes. (2) Reflects adjusted annualized EBITDA divided by the sum of cash interest and preferred dividends, if any.
Leverage (1) Cash Fixed Charge Coverage (2) Target Debt to Adjusted EBITDA Ratio of 4.0x – 5.0x
- Typically have used drawings under the revolver to make acquisitions and
replenished revolver availability with long term debt and equity issuances
4.8x for Q1:17 Annualized 4.8x for Q1:17 Annualized
Investor Presentation, June 2017
$20M Term Loan $233M Drawn $700M 4.375% Notes $400M 4.95% Notes $400M 4.50% Notes $600M 5.25% Notes $700M 4.50% Notes $550M 4.75% Notes
$38M $1,017M Available
$425M Term Loan $129M $100M $250M Term Loan
$0 $100 $200 $300 $400 $500 $600 $700 $800 $900 $1,000 $1,100 $1,200 $1,300 $1,400 $1,500 $1,600 $1,700 $1,800 $1,900 $2,000 $2,100 $2,200 $2,300 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029-44 $ Millions
Financial Overview: Conservative Capitalization
32
Debt Maturity Schedule at 6/1/2017
$1.25B Revolving Credit Facility: $233M drawn at 6/1/2017
Approximate balance of amortizing HUD Loans at 12/31/28 with final maturities to 2044
- $1.8B unsecured revolving credit
and term loan facilities
- $1.25B revolver with a May 2021
maturity, and an additional one year option
- $650MM term loans
- $1.0B available as of June 1,
2017 (est)
- No near term bond maturities
- Minimal secured debt
- $54MM of HUD (at 6/1/2017)
- 81% fixed rate debt at 6/1/2017
$20MM
Credit Facility Term Loans
(1) 1) Represents the £100 million term loan at the spot exchange rate of approximately 1.29 at 6/1/2017
Investor Presentation, June 2017
Financial Overview: Conservative Capitalization
33
Financial Covenant Review
- Strong balance sheet with significant cushion
- n all covenants
- Leverage ratio is key covenant
- Defined as “Funded Debt to Total
Asset Value” not to exceed 60%
- Approximately 46% at Q1 2017
- Debt to Adjusted EBITDA is 4.8x for Q1 2017
Key Bond Covenants (1) Key Credit Facility Covenants (1)
(1) Covenants are based on calculations as defined in the Company’s Credit Agreement
Consolidated
Quarter Ending Leverage Ratio Secured Leverage Ratio Unsecured Leverage Ratio Fixed Charge Cov. Ratio Unsecured Interest Cov. Ratio Tangible Net Worth
Requirement: <= 60% <=30% <= 60% >=1.50 to 1 >=2.00 to 1 >$2,348MM June 30, 2016 48% 3% 49% 5.3 5.0 Pass September 30, 2016 48% 1% 52% 5.3 4.3 Pass December 31, 2016 46% 1% 50% 5.3 4.5 Pass March 31, 2017 46% 1% 50% 5.2 4.3 Pass Status Pass Pass Pass Pass Pass Pass
Quarter Ending Debt / Adj. Total Assets Unencumbered Assets / Unsecured Debt Secured Debt / Adj. Total Assets
Requirement: <= 60% >= 150% <= 40% June 30, 2016 47% 209% 2% September 30, 2016 48% 202% 0% December 31, 2016 47% 207% 0% March 31, 2017 47% 206% 0% Status Pass Pass Pass
(1) Covenants are based on calculations as defined in the Company’s Senior Note Indentures
Investor Presentation, June 2017
Financial Overview: Financial Flexibility
34
Capital Markets Accessibility
- Seasoned market issuer
- Senior Unsecured Notes Rated BBB- by S&P and Fitch; Baa3 by Moody’s
Capital Market Activity, 2004 through June 1, 2017
Note: Common Equity includes shares issued under Omega’s DRIP/DSPP and Omega’s ATM/ESP; 2015 Common Equity excludes 52.9MM combined shares and units issued for Aviv on April 1, 2015 (~$3.9B)
Totals
5,010,000 118,488 2,522,137 7,650,625 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Senior Notes 260,000 225,000
- 775,000
- 400,000
- 650,000
1,300,000 700,000 700,000 Preferred Equity 118,488
- Common Equity
74,909 68,019 33,171 138,359 230,574 102,120 221,474 91,363 191,690 338,847 134,954 609,721 260,433 26,503
- 200,000
400,000 600,000 800,000 1,000,000 1,200,000 1,400,000 1,600,000 1,800,000 2,000,000
Investor Presentation, June 2017
Financial Overview: Financial Flexibility
35
Minimize Encumbered Assets
- $10.1B of total undepreciated assets (over 99% unencumbered)
- $1.25B unsecured revolving credit facility
- $650MM unsecured term loans
- $3.35B of long-term bonds
- $54MM of 30+ year amortizing HUD loans
Encumbered Assets as % of Total Gross Assets
(000's) 1Q 2017 Actual Total Assets: 1 $8,842,118 Accumulated Depreciation: 1,306,084 Total Undepreciated Assets: $10,148,202 Encumbered Assets: 2 (85,258) Total Unencumbered Assets: $10,062,944 Encumbered Assets to Total Gross Assets: 0.8% 1) Includes intangibles and AR 2) Assets securing HUD loans
Investor Recap
Investor Presentation, June 2017
Investor Recap
37
- Attractive industry fundamentals
- Consistent and stable free cash flow and conservative capitalization
- Strong portfolio rent coverage
- Geographic and operator diversification
- No upcoming material lease expirations
- Proven track record of acquisitions and growth
- Seasoned capital markets issuer
- No senior note maturities until 2023
- Experienced senior management team with average tenure of 16+ Years
Exhibits
Investor Presentation, June 2017
Exhibit I: Non-GAAP Financial Reconciliation: Adjusted EBITDA Reconciliation
39
Year Ended December 31, 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2016 2017 Net Income...................................................................................................................... $ 55,697 $ 69,374 $ 78,137 $ 82,111 $ 58,436 $ 52,606 $ 120,698 $ 172,521 $ 221,349 $ 233,315 $ 383,367 $ 58,196 $ 109,112 Depreciation and amortization.................................................................................. 32,263 36,056 39,890 44,694 84,623 100,337 112,983 128,646 123,257 210,703 267,062 62,433 69,993 Depreciation and amortization unconsolidated joint venture................................ - - - - - - - - - - 1,107
- 1,658
Interest expense & refinancing costs......................................................................... 47,611 44,092 39,746 39,075 90,602 86,899 106,096 92,048 126,869 183,208 175,561 39,652 47,543 Provision for income taxes......................................................................................... 2,347 (7) (72) - - - - - - 1,211 1,405 247 1,100 EBITDA...................................................................................................................... 137,918 149,515 157,701 165,880 233,661 239,842 339,777 393,215 471,475 628,437 828,502 160,528 229,406 Nursing home revenues.............................................................................................. - - (24,170) (18,430) (7,336) - - - - - -
- -
Nursing home expenses.............................................................................................. - - 27,601 20,632 7,998 653 - - - - -
- -
Litigation/contractual settlement.............................................................................. - - (526) (4,527) (1,111) - - - - - -
- (10,412)
Acquisition costs......................................................................................................... - - - 1,561 1,554 1,204 909 245 3,948 57,525 9,582 3,771 (41) (Gain) loss on assets sold - net................................................................................... (1,354) (1,993) (12,292) (753) 4 (1,670) (11,799) 1,151 (2,863) (6,353) (50,208) (1,571) (7,420) Advocat non-cash accretion investment income...................................................... (1,280) - - - - - - - - - -
- -
Revenue from prepayment penalty/administration fee........................................... - - - - - - - - - - -
- -
Provisions for impairment on equity securities........................................................ - - - - - - - - - - -
- -
Gain from sale of Sun common stock........................................................................ (2,709) - - - - - - - - - -
- -
Advocat non-cash gain on investment restructuring................................................ (3,567) - - - - - - - - - -
- -
Restatement expense................................................................................................. 1,234 - - - - - - - - - -
- -
Lease expiration expense........................................................................................... - - - - - - - - - - -
- -
Adjustment of derivatives to fair value..................................................................... (9,079) - - - - - - - - - -
- -
Advocat one-time straight line adjustment............................................................... - (5,040) - - - - - - - - -
- -
One-time cash revenue............................................................................................... - - (702) - - - (536) (1,405) - - -
- -
One-time non-cash deferred mortgage interest income.......................................... - - - - - - (236) - (585) -
- -
FIN 46R adjustment..................................................................................................... - (296) (90) - - - - - - -
- -
Settlement of prior operator's past due obligation.................................................. - - (650) - - - - - - -
- -
Gain on Sale of CSFB Mortgage Certificates.............................................................. - - - - (789) - - - - -
- -
Provisions for real estate impairment....................................................................... 541 1,416 5,584 159 155 26,344 272 415 3,660 17,681 58,726 34,558 7,638 Provisions for uncollectible mortgages, notes and A/R............................................ 944 - 4,248 3,935 - 6,439 - 2,141 2,723 7,871 9,845 5,124 2,404 Restricted Stock amortization expense...................................................................... 4,517 1,425 2,103 1,918 2,211 6,037 5,942 5,942 8,592 11,133 13,790 2,778 3,744 Adjusted EBITDA...................................................................................................... 127,165 $ 145,027 $ 158,807 $ 170,375 $ 236,347 $ 278,849 $ 334,329 $ 401,704 $ 486,950 $ 716,294 $ 870,237 $ 205,188 $ 225,319 $ Proforma Acquisition Income..................................................................................... 11,358 2,646 15,360 30,315 32,807 37,153 45,420 55,696 22,194 70,727 47,335 6,189 151 Adjusted Proforma EBITDA (1)................................................................................ 138,523 $ 147,673 $ 174,167 $ 200,690 $ 269,154 $ 316,002 $ 379,749 $ 457,400 $ 509,144 $ 787,021 $ 917,572 $ 211,377 $ 225,470 $ Cash Interest(2)…………………………………………………………………… 42,174 $ 42,134 $ 37,745 $ 36,077 $ 67,282 $ 81,643 $ 95,822 $ 100,459 $ 119,153 $ 150,915 $ 170,516 $ 38,942 $ 47,030 $ Preferred Dividends…………………………………………….……………….. 9,923 9,923 9,714 9,086 9,086 1,691
- Total Fixed Charges………………………………………………………….
52,097 $ 52,057 $ 47,459 $ 45,163 $ 76,368 $ 83,334 $ 95,822 $ 100,459 $ 119,153 $ 150,915 $ 170,516 $ 38,942 $ 47,030 $ Adjusted EBITDA / Cash Fixed Charge coverage ratio……………………………….. 2.4 x 2.8 x 3.3 x 3.8 x 3.1 x 3.3 x 3.5 x 4.0 x 4.1 x 4.7 x 5.1 x 5.3 x 4.8 x Adjusted Proforma EBITDA / Cash Fixed Charge coverage ratio……………………………….. 2.7 x 2.8 x 3.7 x 4.4 x 3.5 x 3.8 x 4.0 x 4.6 x 4.3 x 5.2 x 5.4 x 5.4 x 4.8 x (1) Adjusted Proforma EBITDA assumes all new investments in each respective year had closed on January 1 of that respective year. (2) Excludes interest refinance costs such as early extingishment premiums and amortization of deferred financing costs. Three Monthes Ended March 31,
Investor Presentation, June 2017
Exhibit I: Non-GAAP Financial Reconciliation (cont’d): Leverage Reconciliation
40
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2016 2017 Funded Debt Revolving Line of Credit - secured.......................................................... 150,000 $ 48,000 $ 63,500 $ 94,100 $
- $
- $
- $
- $
- $
- $
- $
- $
- $
Revolving Line of Credit - unsecured......................................................
- 272,500
158,000 326,000 85,000 230,000 190,000 530,000 123,000 Term Loan - secured................................................................................
- 100,000
- 2012 Term Loan - unsecured...................................................................
- 100,000
200,000
- 2014 Term Loan - unsecured Trache 1...................................................
- 200,000
200,000 200,000 200,000 200,000 2015 Term Loan - unsecured Trache 2...................................................
- 200,000
200,000 200,000 200,000 2016 Term Loan - unsecured Trache 3...................................................
- 350,000
350,000 350,000 2015 OP Term Loan - unsecured.............................................................
- 100,000
100,000 100,000 100,000 2015 7 Yr Term Loan - unsecured...........................................................
- 250,000
250,000 250,000 250,000 HUD Debt - secured (1)............................................................................
- 180,890
279,558 335,711 280,425 237,881 56,204 54,955 55,895 54,636 GEMSA - secured.....................................................................................
- 180,000
- 180,000
- Other Borrowings - secured....................................................................
- 59,354
- Industrial Revenue Bonds - unsecured..................................................
2,410 1,995
- Subordinated Debt - unsecured (2)(5)....................................................
- 20,000
20,000 20,000 20,000 20,000 20,000 20,000 20,000 20,000 Notes - unsecured (3)(4).......................................................................... 485,000 485,000 485,000 485,000 950,000 950,000 1,175,000 1,175,000 1,825,000 2,350,000 3,053,000 2,350,000 3,053,000 Total Funded Debt 637,410 $ 534,995 $ 548,500 $ 738,454 $ 1,150,890 $ 1,522,058 $ 1,788,711 $ 2,001,425 $ 2,367,881 $ 3,586,204 $ 4,417,955 $ 4,235,895 $ 4,350,636 $ Less: Cash on-hand (729) (1,979) (209) (2,170) (6,921) (351) (1,711) (2,616) (4,489) (5,424) (93,687) (130,434) (40,349) Adjusted Net Funded Debt 636,681 $ 533,016 $ 548,291 $ 736,284 $ 1,143,969 $ 1,521,707 $ 1,787,000 $ 1,998,809 $ 2,363,392 $ 3,580,780 $ 4,324,268 $ 4,105,461 $ 4,310,287 $ Secured Funded Debt (1)......................................................................... 150,000 48,000 63,500 253,454 180,890 279,558 335,711 280,425 237,881 236,204 54,955 235,895 54,636 Unsecured Funded Debt (2)(3)(4)........................................................... 487,410 486,995 485,000 485,000 970,000 1,242,500 1,453,000 1,721,000 2,130,000 3,350,000 4,363,000 4,000,000 4,296,000 Less: Cash on-hand (729) (1,979) (209) (2,170) (6,921) (351) (1,711) (2,616) (4,489) (5,424) (93,687) (130,434) (40,349) Adjusted Net Funded Debt 636,681 $ 533,016 $ 548,291 $ 736,284 $ 1,143,969 $ 1,521,707 $ 1,787,000 $ 1,998,809 $ 2,363,392 $ 3,580,780 $ 4,324,268 $ 4,105,461 $ 4,310,287 $ Net Debt/Adjusted Proforma Annualized EBITDA (2) 4.6x 3.6x 3.1x 3.7x 4.3x 4.8x 4.7x 4.4x 4.6x 4.5x 4.7x 4.9x 4.8x Secured Funded Debt/Adjusted Proforma Annualized EBITDA (2) 1.1x 0.3x 0.4x 1.3x 0.7x 0.9x 0.9x 0.6x 0.5x 0.3x 0.1x 0.3x 0.1x Notes: All debt shown above excludes deferred financing related costs. 1) HUD debt for December 31, 2014, 2013, 2012 and 2011 excludes 13.6 million, $18.1 million, $30.8 million and $24.1 million of adjustments related to the acquisition date fair value premium, respectively. 2) Subordinated debt for December 31, 2016, 2015, 2014, 2013, 2012 and 2011 excludes $0.5 million, $ 0.6 million, $0.7 million, $0.9 million, $1.0 million and $1.2 million of adjustments related to the acquisition date fair value premium, respectively. 3) Unsecured borrowings for 2006 and 2007 excludes FIN 46 debt of $39 million. 4) The 2016 unsecured note balance includes $3 million of notes payable to a seller related to the purchase price consideration. 5) Subordinated debt for March 31, 2017 and 2016 excludes $0.5 million, $0.6 million million of adjustments related to the acquisition date fair value premium, respectively. Year Ended December 31, Three Monthes Ended March 31,
Investor Presentation, June 2017
Exhibit 2: Growth of Per Share AFFO, FAD and Dividends (10 Years)
41
Quarterly Annually Quarter Ended Ending Share Price
- Div. *
Yield AFFO/ Share Dividend Payout Ratio FAD/ Share FAD Payout Ratio Omega AFFO Guidance 1 AFFO/ Share % Change FAD/ Share % Change Annual Dividend % Change 2007 3/31/2007 $17.15 6.1% 0.3375 $ 0.27 $ 80.0% 0.3111 $ 86.8% $1.32 - $1.36 6/30/2007 $15.83 6.8% 0.3365 $ 0.27 80.2% 0.3141 $ 86.0% 9/30/2007 $15.53 7.0% 0.3528 $ 0.28 80.0% 0.3299 $ 84.9% 12/31/2007 $16.05 7.0% 0.3535 $ 0.29 82.0% 0.3387 $ 85.6% $1.38 11.3% $1.29 9.8% $1.11 13.3% 2008 3/31/2008 $17.36 6.7% 0.3639 $ 0.30 $ 82.4% 0.3612 $ 83.1% $1.41 - $1.43 6/30/2008 $16.65 7.2% 0.3816 $ 0.30 78.6% 0.3709 $ 80.9% 9/30/2008 $19.66 6.1% 0.3387 $ 0.30 88.6% 0.3079 $ 97.4% 12/31/2008 $15.97 7.5% 0.3702 $ 0.30 81.0% 0.3354 $ 89.4% $1.45 5.4% $1.38 6.3% $1.20 8.1% 2009 3/31/2009 $14.08 8.5% 0.3701 $ 0.30 $ 81.1% 0.3550 $ 84.5% $1.47 - $1.50 6/30/2009 $15.52 7.7% 0.3714 $ 0.30 80.8% 0.3569 $ 84.1% 9/30/2009 $16.02 7.5% 0.3657 $ 0.30 82.0% 0.3529 $ 85.0% 12/31/2009 $19.45 6.2% 0.3604 $ 0.32 88.8% 0.3401 $ 94.1% $1.47 0.9% $1.40 2.1% $1.22 1.7% 2010 3/31/2010 $19.49 6.6% 0.3766 $ 0.32 $ 85.0% 0.3704 $ 86.4% $1.60 - $1.68 6/30/2010 $19.93 6.4% 0.3652 $ 0.36 98.6% 0.3957 $ 91.0% 9/30/2010 $22.45 6.4% 0.4531 $ 0.37 81.7% 0.4218 $ 87.7% 12/31/2010 $22.44 6.6% 0.4566 $ 0.37 81.0% 0.4074 $ 90.8% $1.65 12.5% $1.60 13.6% $1.42 16.4% 2011 3/31/2011 $22.34 6.6% 0.4432 $ 0.38 $ 85.7% 0.4009 $ 94.8% $1.80 - $1.86 6/30/2011 $21.01 7.2% 0.4748 $ 0.40 84.2% 0.4345 $ 92.1% 9/30/2011 $15.93 10.0% 0.4769 $ 0.40 83.9% 0.4392 $ 91.1% 12/31/2011 $19.35 8.3% 0.4963 $ 0.41 82.6% 0.4623 $ 88.7% 1.89 $ 14.5% $1.74 8.9% $1.59 12.0% 2012 3/31/2012 $21.26 7.7% 0.5469 $ 0.42 $ 76.8% 0.4738 $ 88.6% $2.06 - $2.12 6/30/2012 $22.50 7.5% 0.5252 $ 0.42 80.0% 0.4535 $ 92.6% 9/30/2012 $22.73 7.4% 0.5353 $ 0.44 82.2% 0.4702 $ 93.6% 12/31/2012 $23.85 7.4% 0.5776 $ 0.45 77.9% 0.5236 $ 85.9% 2.18 $ 15.3% $1.92 10.6% $1.73 8.8% 2013 3/31/2013 $30.36 5.9% 0.6313 $ 0.46 $ 72.9% 0.5739 $ 80.2% $2.45 - $2.50 6/30/2013 $31.02 5.9% 0.6227 $ 0.47 75.5% 0.5614 $ 83.7% 9/30/2013 $29.87 6.3% 0.6260 $ 0.48 76.7% 0.5682 $ 84.5% 12/31/2013 $29.80 6.4% 0.6471 $ 0.49 75.7% 0.5861 $ 83.6% $2.53 15.9% $2.29 19.2% $1.90 9.8% 2014 3/31/2014 $33.52 5.8% 0.7112 $ 0.50 $ 70.3% 0.6506 $ 76.9% $2.69 - $2.72 6/30/2014 $36.86 5.4% 0.6859 $ 0.51 74.4% 0.6257 $ 81.5% 9/30/2014 $34.19 6.0% 0.7320 $ 0.52 71.0% 0.6690 $ 77.7% 12/31/2014 $39.07 5.3% 0.7232 $ 0.53 73.3% 0.6621 $ 80.0% $2.85 12.9% 2.61 $ 13.9% $2.06 8.4% 2015 3/31/2015 $40.57 5.2% 0.7084 $ 0.54 $ 76.2% 0.6492 $ 83.2% $2.98 - $3.04 6/30/2015 $34.33 6.3% 0.7696 $ 0.55 71.5% 0.7000 $ 78.6% 9/30/2015 $35.15 6.3% 0.7913 $ 0.56 70.8% 0.7168 $ 78.1% 12/31/2015 $34.98 6.4% 0.8067 $ 0.57 70.7% 0.7237 $ 78.8% $3.08 7.8% 2.79 $ 7.0% $2.22 7.8% 2016 3/31/2016 $35.30 6.5% 0.8336 $ 0.58 $ 69.6% 0.7488 $ 77.5% $3.25 - $3.30 6/30/2016 $33.95 6.8% 0.8684 $ 0.60 69.1% 0.7731 $ 77.6% 9/30/2016 $35.45 6.8% 0.8327 $ 0.61 73.3% 0.7477 $ 81.6% 12/31/2016 $31.26 7.8% 0.8803 $ 0.62 70.4% 0.7965 $ 77.8% $3.42 11.0% 3.07 $ 9.9% $2.41 8.6% 2017 3/31/2017 $32.99 7.5% 0.8569 $ 0.63 $ 73.5% 0.7730 $ 81.5% $3.40 - $3.44
- 1. Except for 2015, guidance provided at the beginning of each fiscal year
* Based on the annualized dividend announced the previous quarter
- No. of consecutive quarterly dividends paid since 2003:
55
- No. of quarterly dividend increases since 2003:
41
- No. of consecutive quarterly dividend increases:
19
Investor Presentation, June 2017
Exhibit 3: DRIP/DSPP and Equity Shelf Program (ESP) Activity
42
Dividend Reinvestment Optional/Initial Purchases/Waiver Total Purchases Remaining Date Shares
- Avg. Price
Net Proceeds Shares
- Avg. Price
Net Proceeds Shares
- Avg. Price
Proceeds Authorized 1994 104,000 22.644 $ 2,355,000 $ 1995 964,000 24.148 $ 23,279,000 $ 1996 482,000 26.562 $ 12,803,000 $ 1997 53,000 31.717 $ 1,681,000 $ 1998 58,000 31.586 $ 1,832,000 $ 1999 to 2004 69,232 6.879 $ 476,277 $ 56,075 11.069 $ 620,717 $ 125,307 8.754 $ 1,096,994 $ 2005 to 2008 100,376 14.243 $ 1,429,665 $ 6,288,189 14.591 $ 91,748,994 $ 6,388,564 14.585 $ 93,178,659 $ 2009 54,888 15.345 $ 842,261 $ 1,636,690 16.170 $ 26,465,921 $ 1,691,578 16.144 $ 27,308,181 $ 2010 47,110 19.812 $ 933,356 $ 2,913,613 20.458 $ 59,605,405 $ 2,960,723 20.447 $ 60,538,761 $ 2011 687,944 18.432 $ 12,680,187 $ 2,164,804 21.521 $ 46,588,707 $ 2,852,748 20.776 $ 59,268,894 $ 9,753,789 2012 Q1 122,659 21.308 $ 2,613,679 $ 542,256 21.444 $ 11,628,171 $ 664,915 21.419 $ 14,241,850 $ 2012 Q2 152,992 21.134 $ 3,233,287 $ 2,388,543 21.570 $ 51,521,070 $ 2,541,535 21.544 $ 54,754,357 $ 2012 Q3 259,377 23.224 $ 6,023,642 $ 1,324,750 23.505 $ 31,137,733 $ 1,584,127 23.459 $ 37,161,374 $ 2012 Q4 264,054 21.272 $ 5,617,010 $ 7,395 22.530 $ 166,610 $ 271,449 21.306 $ 5,783,619 $ 4,691,763 2013 Q1 205,131 27.419 $ 5,624,569 $ 1,110,196 27.669 $ 30,718,513 $ 1,315,327 27.630 $ 36,343,082 $ 14,732,238 2013 Q2 143,371 35.969 $ 5,156,940 $ 3,726 32.998 $ 122,951 $ 147,097 35.894 $ 5,279,892 $ 14,585,141 2013 Q3 208,135 28.965 $ 6,028,651 $ 6,933 30.835 $ 213,779 $ 215,068 29.025 $ 6,242,430 $ 14,370,073 2013 Q4 245,280 31.669 $ 7,767,674 $ 7,635 31.287 $ 238,875 $ 252,915 31.657 $ 8,006,549 $ 14,117,158 2014 Q1 166,893 30.558 $ 5,099,966 $ 825,867 32.019 $ 26,443,416 $ 992,760 31.773 $ 31,543,382 $ 13,124,398 2014 Q2 131,559 35.536 $ 4,675,120 $ 274,221 34.988 $ 9,594,531 $ 405,780 35.166 $ 14,269,651 $ 12,718,618 2014 Q3 33,673 37.305 $ 1,256,154 $ 511,770 37.528 $ 19,205,473 $ 545,443 37.514 $ 20,461,628 $ 12,173,175 2014 Q4 134,229 37.458 $ 5,027,936 $ 5,287 37.704 $ 199,339 $ 139,516 37.467 $ 5,227,275 $ 12,033,659 2015 Q1 127,691 40.080 $ 5,117,817 $ 7,453 40.979 $ 305,415 $ 135,144 40.129 $ 5,423,232 $ 11,898,515 2015 Q2 113,944 38.571 $ 4,394,880 $ 563,528 36.037 $ 20,307,897 $ 677,472 36.463 $ 24,702,777 $ 11,221,043 2015 Q3 159,466 36.300 $ 5,788,536 $ 821,605 36.237 $ 29,772,866 $ 981,071 36.248 $ 35,561,402 $ 10,239,972 2015 Q4 323,572 32.194 $ 10,417,194 $ 2,066,572 36.179 $ 74,766,555 $ 2,390,144 35.640 $ 85,183,749 $ 7,849,828 2016 Q1 530,998 28.472 $ 15,118,628 $ 128,910 35.469 $ 4,572,266 $ 659,908 29.839 $ 19,690,894 $ 7,189,920 2016 Q2 342,592 32.385 $ 11,094,842 $ 1,894,065 33.087 $ 62,669,208 $ 2,236,657 32.980 $ 73,764,050 $ 4,953,263 2016 Q3 242,884 36.871 $ 8,955,279 $ 3,730,095 34.220 $ 127,643,733 $ 3,972,979 34.382 $ 136,599,012 $ 980,284 2016 Q4 321,862 28.774 $ 9,261,193 $ 23,869 30.426 $ 726,227 $ 345,731 28.888 $ 9,987,420 $ 634,553 Jan-17
- $
- $
6,571 32.850 $ 215,860 $ 6,571 32.850 $ 215,860 $ 17,493,429 Feb-17 216,413 30.573 $ 6,616,308 $ 7,606 30.881 $ 234,884 $ 224,019 30.583 $ 6,851,192 $ 17,269,410 Mar-17
- $
- $
8,565 31.314 $ 268,208 $ 8,565 31.314 $ 268,208 $ 17,260,845 Apr-17
- $
- $
8,036 34.472 $ 277,014 $ 8,036 34.472 $ 277,014 $ 17,252,809 May-17 350,614 32.995 $ 11,568,649 $ 7,298 33.329 $ 243,233 $ 357,912 33.002 $ 11,811,882 $ 16,894,897 Total DRIP / DSPP: 36,760,062 25.381 $ 932,993,269 $
Investor Presentation, June 2017
Exhibit 3: DRIP/DSPP and Equity Shelf Program (ESP) Activity (cont’d)
43
ATM/ESP Program Program Settlement Year / Month Total Shares Average Price (Net) Gross Proceeds 1) $100MM 2009 1,412,835 $17.16 24,250,810 $ 2010 3,786,565 $19.99 75,699,809 Program #1 Total 5,199,400 $19.22 99,950,620 $ 2) $140MM 2010 3,078,808 $21.67 66,712,751 $ 2011 1,419,149 $22.61 32,093,672 2012 758,719 $21.27 16,135,656 Program #2 Total 5,256,676 $21.87 114,942,079 $ 3) $245MM 2012 2,639,643 $24.10 63,613,501 $ 2013 983,766 $28.29 27,827,048 Program #3 Total 3,623,409 $25.24 91,440,548 $ 4) $250MM 2013 5,520,047 $30.87 170,392,847 $ 2014 1,848,170 $34.33 63,451,652 Program #4 Total 7,368,217 $31.74 233,844,499 $ 5) $500MM 2016 655,635 $31.10 20,392,064 $ 2017 227,453 $31.12 7,079,388 $ Program #5 Total 883,088 $31.11 27,471,452 $ ATM/ESP Grand Totals 22,330,790 $24.19 540,177,746 $